Compare Lockheed Martin Corporation (LMT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs BIO-TECHNE Corp — how do they compare? Lockheed Martin Corporation trades at $504.65 (market cap $117.48B), while BIO-TECHNE Corp trades at $71.65 (market cap $11.16B). The key difference: Lockheed Martin Corporation is far larger — about 10.5× BIO-TECHNE Corp's market cap, and Lockheed Martin Corporation pays the higher dividend (2.71%). Which is the better fit depends on your goals.
| LMT | TECH | |
|---|---|---|
Market Cap | $117.48B | $11.16B |
Sector | Industrials | Health |
52-Week High | $676.70 | $72.12 |
52-Week Low | $410.74 | $43.31 |
Enterprise Value | $136.28B | $11.24B |
Dividend Yield | 2.71% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $509.44, showing modest daily gains of 0.13%. The stock faces bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though Q3 2025 exceeded expectations. Revenue growth remains steady, reaching $75.05B in 2025, while net margins have compressed to 6.38%. Analyst sentiment is strongly positive with 57% buy ratings and a $614 consensus target, supported by recent contract wins and new product launches like the PAC-3 ACE interceptor.
LMT offers defensive exposure to elevated defense spending with a $194B backlog, but faces execution risks from margin pressure and debt levels. The stock trades at a premium 24.6x P/E with technical weakness near support at $504. Upside depends on Q2 earnings beat and defense budget sustainability amid geopolitical tensions.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
